2 164

Cited 277 times in

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

Authors
 Atsushi Ohtsu  ;  Jaffer A. Ajani  ;  Yu-Xian Bai  ;  Yung-Jue Bang  ;  Hyun-Cheol Chung  ;  Hong-Ming Pan  ;  Tarek Sahmoud  ;  Lin Shen  ;  Kun-Huei Yeh  ;  Keisho Chin  ;  Kei Muro  ;  Yeul Hong Kim  ;  David Ferry  ;  Niall C. Tebbutt  ;  Salah-Eddin Al-Batran  ;  Heind Smith  ;  Chiara Costantini  ;  Syed Rizvi  ;  David Lebwohl  ;  Eric Van Cutsem 
Citation
 JOURNAL OF CLINICAL ONCOLOGY, Vol.31(31) : 3935-3943, 2013 
Journal Title
 JOURNAL OF CLINICAL ONCOLOGY 
ISSN
 0732-183X 
Issue Date
2013
Abstract
PURPOSE: The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer. This international, double-blind, phase III study compared everolimus efficacy and safety with that of best supportive care (BSC) in previously treated advanced gastric cancer. PATIENTS AND METHODS: Patients with advanced gastric cancer that progressed after one or two lines of systemic chemotherapy were randomly assigned to everolimus 10 mg/d (assignment schedule: 2:1) or matching placebo, both given with BSC. Randomization was stratified by previous chemotherapy lines (one v two) and region (Asia v rest of the world [ROW]). Treatment continued until disease progression or intolerable toxicity. Primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), overall response rate, and safety. RESULTS: Six hundred fifty-six patients (median age, 62.0 years; 73.6% male) were enrolled. Median OS was 5.4 months with everolimus and 4.3 months with placebo (hazard ratio, 0.90; 95% CI, 0.75 to 1.08; P = .124). Median PFS was 1.7 months and 1.4 months in the everolimus and placebo arms, respectively (hazard ratio, 0.66; 95% CI, 0.56 to 0.78). Common grade 3/4 adverse events included anemia, decreased appetite, and fatigue. The safety profile was similar in patients enrolled in Asia versus ROW. CONCLUSION: Compared with BSC, everolimus did not significantly improve overall survival for advanced gastric cancer that progressed after one or two lines of previous systemic chemotherapy. The safety profile observed for everolimus was consistent with that observed for everolimus in other cancers.
Full Text
http://jco.ascopubs.org/content/31/31/3935
DOI
10.1200/JCO.2012.48.3552
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/89039
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse